IMU 0.00% 4.8¢ imugene limited

Herceptin patent

  1. 1,305 Posts.
    lightbulb Created with Sketch. 220
    The patent for trastuzumab (Herceptin) has expired in Europe and will expire in the US in 2019. There are a number of companies who are now making trastuzumab biosimilars, eg. Celltrion in Korea and Biocad in Russia - so expect the price to drop.

    An advantage of the treatment combining both Herceptin and Tyverbis is that the two drugs cost
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
4.8¢
Change
0.000(0.00%)
Mkt cap ! $356.9M
Open High Low Value Volume
4.9¢ 4.9¢ 4.8¢ $328.5K 6.792M

Buyers (Bids)

No. Vol. Price($)
45 5443565 4.8¢
 

Sellers (Offers)

Price($) Vol. No.
4.9¢ 2171910 5
View Market Depth
Last trade - 16.10pm 04/10/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.